3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
86
Recurrence
18
Neoplasms
6
Neoplasms, Plasma Cell
3
Lymphoma, Non-Hodgkin
3
Sarcoma, Kaposi
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Leukemia, Myeloid, Acute
2
Immunoglobulin Light-chain Amyloidosis
2
Chromosome 17 deletion
2
Burkitt Lymphoma
2
Acquired Immunodeficiency Syndrome
2
Waldenstrom Macroglobulinemia
1
Smoldering Multiple Myeloma
1
Proteostasis Deficiencies
1
Plasmacytoma
1
Plasmablastic Lymphoma
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multi-centric Castleman's Disease
1
Malignant Plasma Cell Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Myelomonocytic, Chronic
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Epstein-Barr Virus Infections
1
Interventions
Dexamethasone
3
daratumumab
2
Lenalidomide
2
pomalidomide
1
navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
cc-486
1
carfilzomib
1
auricularum
1
Specimen Handling
1
Radiotherapy
1
Immunotherapy, Adoptive
1
Calcium Dobesilate
1
Bortezomib
1
Biopsy
1
2-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Plasmacytoma
×
pomalidomide
×
1 year
×
Clear all
NCT01946477
2026-05-22
POM MM 014
Celgene
Phase 2
Completed
186 enrolled
17 charts